Diagnostic value of partial exome sequencing in developmental disorders

Although intellectual disability is one of the major indications for genetic counselling, there are no homogenous diagnostic algorithms for molecular testing. While whole exome sequencing is increasingly applied, we questioned whether analyzing a partial exome, enriched for genes associated with Mendelian disorders, might be a valid alternative approach that yields similar detection rates but requires less sequencing capacities. Within this context 106 patients with different intellectual disability forms were analyzed for mutations in 4.813 genes after pre-exclusion of copy number variations by array-CGH. Subsequent variant interpretation was performed in accordance with the ACMG guidelines. By this, a molecular diagnosis was established in 34% of cases and candidate mutations were identified in additional 24% of patients. Detection rates of causative mutations were above 30%, regardless of further symptoms, except for patients with seizures (23%). We did not detect an advantage from partial exome sequencing for patients with severe intellectual disability (36%) as compared to those with mild intellectual disability (44%). Specific clinical diagnoses pre-existed for 20 patients. Of these, 5 could be confirmed and an additional 6 cases could be solved, but showed mutations in other genes than initially suspected. In conclusion partial exome sequencing solved >30% of intellectual disability cases, which is similar to published rates obtained by whole exome sequencing. The approach therefore proved to be a valid alternative to whole exome sequencing for molecular diagnostics in this cohort. The method proved equally suitable for both syndromic and non-syndromic intellectual disability forms of all severity grades.

[1]  S. Pajusalu,et al.  Large gene panel sequencing in clinical diagnostics—results from 501 consecutive cases , 2018, Clinical genetics.

[2]  Daniele Merico,et al.  Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test , 2017, Genetics in Medicine.

[3]  Renzo Guerrini,et al.  Lissencephaly: Expanded imaging and clinical classification , 2017, American journal of medical genetics. Part A.

[4]  M. State,et al.  Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield , 2017, Molecular Psychiatry.

[5]  Deciphering Developmental Disorders Study,et al.  Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.

[6]  Joan,et al.  Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.

[7]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[8]  R. Horvath,et al.  Novel homozygous RARS2 mutation in two siblings without pontocerebellar hypoplasia – further expansion of the phenotypic spectrum , 2016, Orphanet Journal of Rare Diseases.

[9]  M. Roselló,et al.  High diagnostic yield of syndromic intellectual disability by targeted next-generation sequencing , 2016, Journal of Medical Genetics.

[10]  R. Płoski,et al.  Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations , 2016, Journal of Translational Medicine.

[11]  R. Guerreiro,et al.  RARS2 mutations in a sibship with infantile spasms , 2016, Epilepsia.

[12]  C. Pérez-Cerdá,et al.  Molecular diagnosis of glycogen storage disease and disorders with overlapping clinical symptoms by massive parallel sequencing , 2016, Genetics in Medicine.

[13]  A. Rump,et al.  Mutations in EXOSC2 are associated with a novel syndrome characterised by retinitis pigmentosa, progressive hearing loss, premature ageing, short stature, mild intellectual disability and distinctive gestalt , 2016, Journal of Medical Genetics.

[14]  F. Pidcock,et al.  Functional outcomes in Rett syndrome , 2016, Brain and Development.

[15]  Francesca Forzano,et al.  A specific mutation in TBL1XR1 causes Pierpont syndrome , 2016, Journal of Medical Genetics.

[16]  W. Chung,et al.  Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.

[17]  Gert Matthijs,et al.  Guidelines for diagnostic next-generation sequencing , 2015, European Journal of Human Genetics.

[18]  Alessandra Renieri,et al.  Targeted Next‐Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability , 2015, Human mutation.

[19]  Saudi Mendeliome Group Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases , 2015, Genome Biology.

[20]  Mohammed Alhashem,et al.  Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases , 2015, Genome Biology.

[21]  Emil Alexov,et al.  Structural, Dynamical, and Energetical Consequences of Rett Syndrome Mutation R133C in MeCP2 , 2015, Comput. Math. Methods Medicine.

[22]  Alejandro Sifrim,et al.  Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data , 2015, The Lancet.

[23]  Steven P. Angus,et al.  Redefining the MED13L syndrome , 2015, European Journal of Human Genetics.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  Tomas W. Fitzgerald,et al.  Large-scale discovery of novel genetic causes of developmental disorders , 2014, Nature.

[26]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[27]  Eric Vilain,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[28]  J. Moeschler,et al.  Comprehensive Evaluation of the Child With Intellectual Disability or Global Developmental Delays , 2014, Pediatrics.

[29]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[30]  G. Houge,et al.  Dosage changes of MED13L further delineate its role in congenital heart defects and intellectual disability , 2013, European Journal of Human Genetics.

[31]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[32]  D. Horn,et al.  Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study , 2012, The Lancet.

[33]  S. Gallati,et al.  Targeted next generation sequencing as a diagnostic tool in epileptic disorders , 2012, Epilepsia.

[34]  B. Burton,et al.  The Coffin–Siris syndrome: A proposed diagnostic approach and assessment of 15 overlapping cases , 2012, American journal of medical genetics. Part A.

[35]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[36]  Christian Gilissen,et al.  A de novo paradigm for mental retardation , 2010, Nature Genetics.

[37]  H. Ropers Genetics of early onset cognitive impairment. , 2010, Annual review of genomics and human genetics.

[38]  K. Kernohan,et al.  ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. , 2010, Developmental cell.

[39]  R. Hennekam,et al.  Etiology of mental retardation in children referred to a tertiary care center: a prospective study. , 2005, American journal of mental retardation : AJMR.

[40]  J. Goodship,et al.  Missense Mutations and Gene Interruption in PROSIT240, a Novel TRAP240-Like Gene, in Patients With Congenital Heart Defect (Transposition of the Great Arteries) , 2003, Circulation.

[41]  S Schwartz,et al.  Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. , 1997, American journal of medical genetics.

[42]  F. Baas,et al.  RARS2 Mutations: Is Pontocerebellar Hypoplasia Type 6 a Mitochondrial Encephalopathy? , 2017, JIMD reports.

[43]  Steven P. Angus,et al.  Rede fi ning the MED 13 L syndrome , 2015 .

[44]  G. Arbanas Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[45]  H. Ropers,et al.  Genetics of recessive cognitive disorders. , 2014, Trends in genetics : TIG.